FederalDue in 8 days · Sep 25, 2026
Employment and Training Administration
The Employment and Training Administration (ETA) intends to award a cooperative agreement to the National Association of State Workforce Agencies' Center for Employment Security Education and Research (NASWA/CESER) for continued operations of the Unemployment Insurance (UI) Integrity Center of Excellence (Integrity Center). The Consolidated Appropriations Act, 2026 (Public Law 119-75) provides Fiscal Year (FY) 2026 funding for federal agencies and provides "... $9,000,000 for continued support of the Unemployment Insurance Integrity Center of Excellence... ." as part of the Department of Labor's appropriation for State Unemployment Insurance and Employment Service Operations. The UI Integrity Center has been operated by the NASWA/CESER since FY 2017. NASWA/CESER is a 501(c)(3) entity incorporated in August 1994 as an education and research arm of the NASWA, which is a national organization of state administrators of the publicly-funded state workforce system and is a leading provider of information technology, education, and research support focused exclusively on UI and workforce development initiatives and activities. The primary mission of the UI Integrity Center is to provide training and technical assistance to states to improve UI program integrity; develop and disseminate UI program integrity resources and promote innovative new tools and products that are transferable and scalable for all states to prevent UI improper payments and enhance fraud prevention solutions; and enable rapid alerts to states on new improper payment practices and fraud schemes as they are identified.
FederalDue in 8 days · Sep 25, 2026
National Institutes of Health
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on developing a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the NCI will support U54 Specialized Centers that together will continue to serve as the hub of the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multidisciplinary basic research projects. The projects should use integrative system level approaches to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. Overarching themes should encompass the interplay between at least two central elements in the metastatic process such as early dissemination, cellular, soluble and/or physical microenvironment crosstalk, dormancy, or mechanisms of responses by metastatic cells to therapies. Studies on all types of cancer are welcome, including rare and pediatric metastatic cancers.Research proposed by MetNet Centers is expected to advance our understanding towards a more comprehensive appreciation of metastasis as a whole body, systems-level problem.
FederalDue in 11 days · Sep 28, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: Initially created in fiscal year 2019 (FY19), the Kidney Cancer Research Program (KCRP) Academy of Kidney Cancer Investigators (AKCI) is a unique interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The Academy pairs Early Career Scholars (ECS) with established investigators (Designated Mentors) under the oversight of the AKCI Leadership Team, a Designated Mentor Panel, and the Kidney Cancer Patient Advocates Panel. The AKCI’s overarching goal is to conduct innovative and impactful kidney cancer research while also developing a vital resource, a network of highly productive kidney cancer researchers conducting cutting edge research that advances the state of the field in kidney cancer and leads to new treatments for individuals living with kidney cancer.
Distinctive Features:
· Early-Career Scholar: The FY26 KCRP AKCI-ECSA focuses on both the Scholar’s
research and their career potential in the kidney cancer field.
· Designated Mentor: The Designated Mentor must have a strong record of successful mentorship coupled with a strong record of funding (past and present) and publications in kidney cancer research.
· Preliminary Data: Preliminary data to support the feasibility of the research and approaches are required; however, these data do not need to be derived from the kidney cancer research field.
Amount not specifiedOfficial notice ↗ FederalDue in 11 days · Sep 28, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Idea Development Award (IDA) supports the development of high-impact ideas that advance the understanding of kidney cancer and ultimately lead to improved patient outcomes. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in kidney cancer research.
Distinctive Features:
· Partnering Principal Investigator Option: Supports meaningful and productive partnerships between two investigators, termed the Initiating Principal Investigator (PI) and Partnering PI, collaborating on a single application. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Amount not specifiedOfficial notice ↗ FederalDue in 11 days · Sep 28, 2026
National Institutes of Health
This is a non-competitive funding opportunity intended to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreement award to Massachusetts General Hospital to support the renewal of the Post-Stroke Vascular Cognitive Impairment & Dementia (VCID) program, an ongoing, multi-site clinical research initiative designed to elucidate mechanisms linking stroke to subsequent cognitive impairment and dementia. The award will enable completion of the scientific aims initiated under the original U19 cooperative agreement (RFA-NS-19-012) and advance national priorities described in the National Plan to Address Alzheimer"s Disease.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from Massachusetts General Hospital. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Amount not specifiedOfficial notice ↗ FederalDue in 11 days · Sep 28, 2026
U.S. Mission to Bosnia and Herzegovina
INL announces a funding opportunity for qualified individuals to provide expert advisory and mentoring support to specialized anti-organized crime and corruption departments in Bosnia and Herzegovina, covering both the Federation of Bosnia and Herzegovina and Republika Srpska. Criminal networks in Bosnia and Herzegovina have documented links to Western Hemisphere cartels that launder drug proceeds and shield corrupt officials, directly threatening U.S. security and economic interests. Bosnia and Herzegovina sits on the Balkan Route, a key corridor for narcotics, weapons, and migrant smuggling.The selected expert or experts will strengthen prosecutorial capacity within the Federation of Bosnia and Herzegovina's Specialized Department for Corruption and Organized Crime, known as POSKOK, and its Republika Srpska counterpart by delivering structured advisory sessions, participating in legal reform working groups, and providing case-based mentoring to prosecutors, judges, and investigators. Key objectives include strengthening prosecutorial methodology aligned with the Federation of Bosnia and Herzegovina 2014 Law on the Suppression of Corruption and Organized Crime, and developing a structured case prioritization framework to help departments manage complex, high-level caseloads and identify cases with a U.S. nexus.
$50,000 – $75,000Official notice ↗ FederalDue in 11 days · Sep 28, 2026
Library of Congress
This funding opportunity is authorized under the “Legislative Branch Appropriations Act of 2023” (Pub. L. 117-389 (H.R. 8237)), subject to availability of funding. The resulting awards will be subject to the Library of Congress Regulation (LCR) 7-310. In addition, while the Library, as a legislative agency, is not subject to 2 CFR 200 – Uniform Administrative Requirements, Costs Principles and Audit Requirements for Federal Awards, the resulting awards will be subject to selective provisions of 2 CFR 200 as determined by the Library and indicated in this NOFO.
About the Library of Congress
The Library of Congress is the largest library in the world, with millions of books, films and video, audio recordings, photographs, newspapers, maps and manuscripts in its collections. The Library is the main research arm of the U.S. Congress. It is the nation’s oldest federal cultural institution.
The Library’s mission is to engage, inspire, and inform Congress and the American people with a universal and enduring source of knowledge and creativity.
About the Teaching with Primary Sources Program (TPS)
The Teaching with Primary Sources program (www.loc.gov/teachers) has been the Library of Congress’s premier educational grant program since 2006. The goals of the program have included providing instructional materials, tools, education and professional development that enhance teachers’ ability to integrate digitized primary sources from the Library of Congress into instruction that builds student literacy, critical thinking skills, content knowledge and ability to conduct original research. Since the establishment of the Center for Learning, Literacy and Engagement in 2018, and the release of the Library’s 2024-2028 Strategic Plan, the TPS goals both influence and reflect the Library’s broader outreach goals.
About the Lewis-Houghton Civics and Democracy Initiative (LHI)
Named in honor of Rep. John R. Lewis (D-GA) and Rep. Amo Houghton (R-NY), the Lewis-Houghton Civics and Democracy Initiative (LHI) is included under the Teaching with Primary Sources (TPS) program. In the joint explanatory statement for the Legislative Branch Appropriations Act, 2023, Congress established the Lewis-Houghton Civics and Democracy Initiative and appropriated funds to the Library of Congress to award grants to eligible organizations within the United States (U.S.) and its territories to develop digitally-enabled, creative arts-driven projects focused on using the digitized primary sources of the Library of Congress to teach history, civics and/or democracy. More information and a description of past LHI-funded projects can be found at: https://www.loc.gov/programs/teachers/about-this-program/teaching-with-primary-sources-partner-program/lewis-houghton/.
TPS Educational Consortium
Grantee organizations become members of the TPS Educational Consortium. They include a wide variety of educational organizations including school districts, libraries, cultural institutions, universities and technology firms that have received Library funding to deliver teacher professional development, create teaching materials and develop apps and online interactives, based on Library of Congress materials.
TPS Consortium members are valued as “Connectors” who help the Library achieve its vision of connecting to all Americans. TPS Consortium members extend the Library’s reach by connecting hundreds of thousands of American educators and learners, including K-12 teachers and their students, to Library of Congress methods and materials. Consortium members collaborate, co-create, share ideas, network and actively participate as an educational community.
Purpose
The purpose of this notice is for the Library of Congress to solicit project proposals from eligible organizations and select awardee organizations that will design and implement educational projects in which the Library’s music or creative arts-related digitized primary sources and other online materials are central to teaching and learning about history, civics, and/or democracy.
Awards made under Lewis-Houghton Civics and Democracy Initiative must include rights-free materials from the Library’s music or creative arts digital collections, to develop curriculum, teaching materials, educational programs, pedagogical approaches, and/or other tools for history, civic and democracy instruction targeted toward middle and high school educators and learners. LHI awards should center on inquiry-driven analysis of primary sources, build learners’ civic skills and foster participation in our nation’s democracy.
In addition to highlighting primary sources from the Library’s collections of music, dance, theater, visual arts, folk arts, film, photography, book arts, arts and literary manuscripts, and/or other creative arts, proposals may also include the use of arts-based pedagogies and other creative approaches. All proposals must expand the body of innovative strategies, tools, and materials for meanin…
FederalDue in 12 days · Sep 29, 2026
National Institutes of Health
The purpose of this Notice of Funding Opportunity (NOFO) is to support the next 5-year award period of the Clinician-Scientist Transdisciplinary Aging Research Coordinating Center (Clin-STAR CC), whose mission is to serve as a national resource for clinician-investigators across specialties and disciplines who are focusing their careers on aging research. This NOFO intends to build upon NIA's substantial investments to foster the development of clinician-scientists across specialties and disciplines. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties and disciplines who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance interdisciplinary research projects in aging. Ultimately, the Clin-STAR CC is intended to provide a multi-faceted national research platform leading to improved patient-centered care for older adults across specialties and disciplines.
FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.
Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.
Distinctive Features:
· For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.
· The research team must include two or more breast cancer consumer advocates.
· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.
Applications must address one of the following focus areas:
· Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.
· Clinical Care: Improving aspects of clinical care and symptom management for ALS.
Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.
Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.
All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.
Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4.
Distinctive Features:
· Clinical trials are required.
· The research team must include two or more breast cancer consumer advocates.
· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.
Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.
Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.
Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the
ALS lived experience community.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Assistance Coordination
The Middle East Regional Cooperation (MERC) Program supports joint scientific research and innovation partnerships between the United States, Israel, and countries across the Middle East and North Africa (MENA). The program funds applied research projects that address shared regional challenges while advancing U.S. economic, technological, and strategic interests. MERC is designed to bring together researchers, technical experts, and institutions to work on projects that go beyond basic research and demonstrate clear potential for application, commercialization, and broader adoption. MERC prioritizes efforts that strengthen U.S. technological leadership, expand opportunities for U.S. businesses, promote the use of U.S. technologies, and build long-term partnerships in the region. The program places strong emphasis on collaboration. All projects must include organizations from Israel and at least one eligible MENA country or territory. MERC welcomes U.S. participation, particularly when it adds technical expertise, supports market expansion for U.S. companies, or helps connect research to markets. Projects should demonstrate a clear plan for using and scaling results and how the outcomes benefit priorities of the United States and the participating countries. Overall, MERC aims to strengthen regional cooperation by supporting high-quality scientific partnerships that produce tangible results. By connecting U.S., Israeli, and MENA organizations, the program helps build networks, promote innovation, and create opportunities for economic growth, peaceful and mutually beneficial collaboration, and long-term stability in the region.
$100,000 – $2,000,000Official notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.
Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers.
Distinctive Features:
Preliminary data are not required.
Due to the blinded nature of the review process, identifying or making references to the Principal Investigator (PI), collaborator(s), or their organization(s) in the proposal Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work (SOW) is prohibited and will result in administrative rejection of the application.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
National Institutes of Health
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications for Centers within the NIDDK Cooperative Centers of Experimental in Hematology (CCEH) Program. Each Center will support one to three Biomedical Research Cores and an Administrative Core, including an Enrichment Program. Each Center is expected to work collaboratively with NIDDK, the Hematology Coordinating Center (HCC), and the other CCEH Centers. The CCEH Program is designed to increase access to critical research resources and expertise unique to nonmalignant hematology research. By providing innovative technology, resources, and expertise to the greater hematology research community, the program will serve as a national hub, aimed at recruiting and retaining both junior scientists just beginning their careers in the field as well as established investigators from other domains.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
National Institutes of Health
This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
FederalDue in 13 days · Sep 30, 2026
National Institutes of Health
This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
FederalDue in 13 days · Sep 30, 2026
National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to establish a Center that trains researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
DARPA - Biological Technologies Office
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.
Amount not specifiedOfficial notice ↗ FederalDue in 13 days · Sep 30, 2026
Office of Naval Research
ONR, ONRG, and MCWL are interested in receiving proposals for Long-Range S&T Projects that offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR, ONRG and MCWL’s broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines.
All responsible sources from academia, industry and the research community worldwide may submit proposals under this BAA. All businesses, both small and large, are encouraged to submit proposals and compete for funding consideration.
Amount not specifiedOfficial notice ↗ FederalDue in 14 days · Oct 1, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Amount not specifiedOfficial notice ↗